Clinical Trial Update: Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and preliminary efficacy of combining Gemtuzumab ozogamicin with Venetoclax in adults with relapsed or refractory CD33-posit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Mylotarg (gemtuzumab ozogamicin)
• Venclyxto (Venetoclax)

Snippet

Sponsor: John Quigley | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED | Results posted: 2025-05-04